About Alanine--glyoxylate aminotransferase
Alanine--glyoxylate aminotransferase (AGXT) is a protein
from Homo sapiens identified by UniProt accession
P21549, 392 residues long.
MolForge cross-references it against 0 known binders and
365 disease associations.
Target properties
| Protein name | Alanine--glyoxylate aminotransferase |
|---|
| UniProt accession | P21549 |
|---|
| Gene | AGXT |
|---|
| Organism | Homo sapiens |
|---|
| Length | 392 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (365)
Diseases linked to this target (Open Targets).
- primary hyperoxaluria type 1 · score 0.87
- primary hyperoxaluria · score 0.68
- alanine glyoxylate aminotransferase deficiency · score 0.45
- nephrolithiasis · score 0.39
- nephrocalcinosis · score 0.37
- nephrotic syndrome · score 0.34
- cardiac arrhythmia · score 0.27
- Abnormality of metabolism/homeostasis · score 0.27
- genetic disorder · score 0.19
- body height · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P21549-F1 | alphafold | PREDICTED | 98.28 | — |
Amino-acid sequence (392 residues)
MASHKLLVTP PKALLKPLSI PNQLLLGPGP SNLPPRIMAA GGLQMIGSMS KDMYQIMDEI KEGIQYVFQT RNPLTLVISG SGHCALEAAL VNVLEPGDSF LVGANGIWGQ RAVDIGERIG ARVHPMTKDP GGHYTLQEVE EGLAQHKPVL LFLTHGESST GVLQPLDGFG ELCHRYKCLL LVDSVASLGG TPLYMDRQGI DILYSGSQKA LNAPPGTSLI SFSDKAKKKM YSRKTKPFSF YLDIKWLANF WGCDDQPRMY HHTIPVISLY SLRESLALIA EQGLENSWRQ HREAAAYLHG RLQALGLQLF VKDPALRLPT VTTVAVPAGY DWRDIVSYVI DHFDIEIMGG LGPSTGKVLR IGLLGCNATR ENVDRVTEAL RAALQHCPKK KL
Explore Alanine--glyoxylate aminotransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets